Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > FINALLY AFTER ALL THESE YEARS, WE ARE FINALLY IN GOOD HANDS!
View:
Post by skys1 on Jan 28, 2022 3:18pm

FINALLY AFTER ALL THESE YEARS, WE ARE FINALLY IN GOOD HANDS!

I don't know how many of you have seen Dr Vera's resume, but it surely is the most impressive I have seen. The fact that such an accomplished, experienced pro would take a look at TLT's ACT and it's potential and want in, is very assuring. IMO, the one void in TLT's resume was the lack of an experienced, accomplished Director of Clinical Development to develope and govern the trials and deal with the FDA etc. Now that we have her expertise I expect at least three of the following four accomplishments this year. BTD, continued positive trial results, an additional new trial for another indication, and lastly some type of deal on funding, licensing or something along commercial developement lines. For sure, I expect the share price to be substantially above where it is now. I believe people are now starting to see this potential and while the rest of the market is tanking, TLT remains near it's yearly high.
Comment by StevenBirch on Jan 28, 2022 3:30pm
I agree Skys, with that resume it would seem like "an additional new trial for another indication" is a slamdunk especially given the timing of her coming on board - it's like a precursor of what is to come. Behind the scenes and in between updates they obviously like what they see. People waiting for confirmation from a news release will have to pay a much steeper price.
Comment by Longholder99 on Jan 28, 2022 4:47pm
Agree Skys1. She wouldnt sign up with a loser. Vera doesnt seem like someone who messes around and is here for a reason.
Comment by Legit62 on Feb 01, 2022 9:49am
she was a sign of faith in this company, our time is now
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250